Test Price
2,800 AED✅ Home Collection Available
ACTA1 Gene Nemaline Myopathy Type 3 Genetic Test in UAE | 2800 AED | DNA Labs UAE – DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via Next Generation Sequencing (NGS) with ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — Available daily from 8 AM to 11 PM across all Emirates.
Clinical Guidance: Telephonic Post-Test Clinical Guidance with a Consultant Medical Geneticist to support result interpretation and next steps.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 — instant confirmation within minutes.
Test Overview & Methodology
The ACTA1 Gene Nemaline Myopathy Type 3 Genetic Test is a definitive molecular diagnostic assay that screens the entire coding region of the ACTA1 gene using Next Generation Sequencing (NGS) technology to identify pathogenic variants associated with autosomal dominant and autosomal recessive nemaline myopathy type 3 — a congenital neuromuscular disorder characterized by muscle weakness, hypotonia, and the presence of nemaline rods on muscle biopsy.
| Feature | Our Test — DHA-Certified | Closest Alternative |
|---|---|---|
| Precision | 99.9% Diagnostic Sensitivity — Full ACTA1 Gene Coverage via NGS | Variable; May Miss Deep Intronic or Regulatory Variants |
| Method | Next Generation Sequencing (NGS) with Clinical-Grade Bioinformatics Pipeline & MLV Confirmation | Sanger Sequencing Only or Targeted Hotspot Panel |
| Speed (TAT) | 3 to 4 Weeks with Expedited Reporting Option Available | 6 to 8 Weeks Standard Turnaround |
| Pre-Test Support | Included Genetic Counselling Session with Pedigree Charting | Often Not Included or Limited to Basic Consent |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh
DHA Registration ID: 9294403 | Consultant Medical Genetics
"A genetic diagnosis provides clarity and direction, but it must be interpreted within the full context of each patient's clinical presentation and family history. This ACTA1 genetic test is a powerful tool for confirming nemaline myopathy type 3, but it does not replace expert clinical correlation or ongoing medical management. I encourage every patient to share results with their neurologist and genetic counsellor to build a comprehensive care plan tailored to their unique needs."
— Lina Osama Zaki Quteineh, DHA 9294403
⚠️ Medication Advisory
Do not discontinue prescribed medication without consulting your doctor. Genetic test results may inform long-term management strategies but must never be used to abruptly alter or stop any current prescribed therapy without direct physician supervision.
🛡️ Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do Not Proceed If:
- Patient is currently hemodynamically unstable or hospitalized in ICU without treating physician clearance.
- Acute febrile illness or active systemic infection within 48 hours — may affect sample integrity.
- Inability to provide informed consent (patient or legal guardian for minors).
- Recent blood transfusion (within 4 weeks) — may introduce donor DNA confounding.
🚨 Emergency Red Flags — Seek Immediate Medical Attention:
- Acute respiratory distress or newly onset dysphagia in a patient with suspected nemaline myopathy.
- Sudden loss of ambulation or significant worsening of muscle weakness within 24–48 hours.
- Signs of malignant hyperthermia susceptibility — urgent anaesthesiology consultation required.
- Cardiac arrhythmia or cardiomyopathy symptoms in confirmed ACTA1-related myopathy.
If you or the patient experience any of the above, please proceed to the nearest emergency department immediately. This genetic test is an elective diagnostic procedure and does not replace emergency medical care.
Patient FAQ & Clinical Guidance
1. What does the ACTA1 gene test diagnose, and who should consider it?
This test identifies pathogenic mutations in the ACTA1 gene responsible for nemaline myopathy type 3, a congenital neuromuscular disorder, and should be considered by individuals with unexplained muscle weakness, hypotonia, or a family history of congenital myopathies seeking definitive molecular diagnosis.
2. Is a genetic counselling session mandatory before the blood draw?
Yes, a pre-test genetic counselling session is mandatory under UAE Federal Decree-Law No. 4 of 2016 on Medical Liability and Federal Law No. 2 of 2019 to draw a comprehensive pedigree chart, discuss potential outcomes, and ensure fully informed consent before any sample is collected for this ACTA1 analysis.
3. How long until I receive my results, and how will they be delivered?
Results are delivered within 3 to 4 weeks via a secure, encrypted online portal with an accompanying telephonic clinical guidance session from a Consultant Medical Geneticist who will walk you through every clinically significant finding in plain language.
UAE Regulatory & Data Privacy Adherence
Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): All genetic data is classified as sensitive personal data. Data is encrypted at rest and in transit (AES-256), stored on UAE-sovereign servers, and never shared with third parties without explicit written consent.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: This laboratory strictly adheres to all provisions governing digital health data, including mandatory pre-test genetic counselling, informed consent protocols, and prohibition of genetic discrimination.
Federal Decree-Law No. 4 of 2016 on Medical Liability: Genetic testing for minors requires documented consent from a legal guardian and a court-approved medical necessity determination. All minor samples are processed under enhanced ethical oversight.
Clinical & Logistical Metadata
| Test Name | ACTA1 Gene Nemaline Myopathy Type 3 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Venous Blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection |
| Methodology Used | Next Generation Sequencing (NGS) with Clinical-Grade Bioinformatics Pipeline & MLV Confirmation |
| ICD-10-CM Code | G71.2 (Congenital myopathy, including nemaline myopathy) |
| LOINC Code | 88554-0 (Gene sequencing – Genetic test) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians